NASDAQ:VKTX - Viking Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.97 -0.68 (-3.46 %) (As of 09/21/2018 03:30 AM ET)Previous Close$19.65Today's Range$18.91 - $20.8552-Week Range$1.21 - $24.00Volume7.26 million shsAverage Volume2.63 million shsMarket Capitalization$1.18 billionP/E Ratio-24.13Dividend YieldN/ABeta2.86 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California. Receive VKTX News and Ratings via Email Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:VKTX CUSIPN/A Webwww.vikingtherapeutics.com Phone858-704-4660 Debt Debt-to-Equity RatioN/A Current Ratio35.18 Quick Ratio35.18 Price-To-Earnings Trailing P/E Ratio-24.13 Forward P/E Ratio-43.11 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.38 per share Price / Book49.92 Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-20,570,000.00 Net MarginsN/A Return on Equity-35.70% Return on Assets-31.72% Miscellaneous Employees14 Outstanding Shares60,660,000Market Cap$1.18 billion Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." How were Viking Therapeutics' earnings last quarter? Viking Therapeutics Inc (NASDAQ:VKTX) released its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. View Viking Therapeutics' Earnings History. When is Viking Therapeutics' next earnings date? Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Viking Therapeutics. What price target have analysts set for VKTX? 7 brokerages have issued 1-year price objectives for Viking Therapeutics' shares. Their predictions range from $15.00 to $43.00. On average, they expect Viking Therapeutics' stock price to reach $27.6667 in the next year. This suggests a possible upside of 45.8% from the stock's current price. View Analyst Price Targets for Viking Therapeutics. What is the consensus analysts' recommendation for Viking Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics. What are Wall Street analysts saying about Viking Therapeutics stock? Here are some recent quotes from research analysts about Viking Therapeutics stock: 1. Maxim Group analysts commented, "VKTX shares are up sharply (~+80%) after announcing positive top-line 12- week P2 data for VK2809, an oral thyroid beta receptor agonist (TRβ), in Non- Alcoholic Fatty Liver Disease (NAFLD) and elevated LDL-C. We have reduced the risk in our model to 30%, from 50% and are increasing our price target to $28, from $14." (9/18/2018) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Viking Therapeutics, Inc." (8/10/2018) Who are some of Viking Therapeutics' key competitors? Some companies that are related to Viking Therapeutics include Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Madrigal Pharmaceuticals (MDGL), Array Biopharma (ARRY), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND) and Reata Pharmaceuticals (RETA). Who are Viking Therapeutics' key executives? Viking Therapeutics' management team includes the folowing people: Dr. Brian Lian, Pres, CEO & Director (Age 52)Mr. Michael Morneau, VP of Fin. & Admin. (Age 53)Ms. Amy Broidrick, Sr. VP of Corp. Devel.Dr. Hiroko Masamune, Chief Devel. Officer (Age 61)Ms. Marianne Mancini, Sr. VP of Clinical Operations When did Viking Therapeutics IPO? (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager. Has Viking Therapeutics been receiving favorable news coverage? News stories about VKTX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Viking Therapeutics. Who are Viking Therapeutics' major shareholders? Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (6.18%), BlackRock Inc. (4.85%), Janus Henderson Group PLC (3.40%), Opaleye Management Inc. (1.98%), Acuta Capital Partners LLC (1.24%) and Millennium Management LLC (1.22%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Matthew W Foehr and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics. Which institutional investors are selling Viking Therapeutics stock? VKTX stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Millennium Management LLC, EAM Global Investors LLC and Bank of America Corp DE. View Insider Buying and Selling for Viking Therapeutics. Which institutional investors are buying Viking Therapeutics stock? VKTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Acuta Capital Partners LLC, Pier Capital LLC, Boxer Capital LLC, Northern Trust Corp, Macquarie Group Ltd. and Bank of New York Mellon Corp. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton, Lawson Macartney and Matthew W Foehr. View Insider Buying and Selling for Viking Therapeutics. How do I buy shares of Viking Therapeutics? Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $18.97. How big of a company is Viking Therapeutics? Viking Therapeutics has a market capitalization of $1.18 billion. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected] MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 227 (Vote Outperform)Underperform Votes: 133 (Vote Underperform)Total Votes: 360MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: Do Tariffs Work?